8-K: Cardiff Oncology Announces Positive Phase 2 Trial Enrollment and First Quarter 2025 Financial Results

Cardiff Oncology reports completion of enrollment in a Phase 2 trial for RAS-mutated metastatic colorectal cancer and provides a business update, including financial results for Q1 2025.

Summary

• Cardiff Oncology announced the completion of enrollment in its Phase 2 CRDF-004 trial evaluating onvansertib plus standard of care for first-line RAS-mutated metastatic colorectal cancer (mCRC).
• The company expanded its intellectual property portfolio with a second patent covering the treatment of all bev-naive patients with mCRC, regardless of RAS mutation status, across all lines of therapy.
• As of March 31, 2025, Cardiff Oncology had $79.9 million in cash and investments, which is projected to fund operations into Q1 2027.
• The Phase 2 CRDF-004 trial reached its targeted enrollment across 41 clinical sites in the U.S.
• Patients in the trial have mCRC and a documented KRAS or NRAS mutation with unresectable disease and are randomized to receive onvansertib plus SoC or SoC alone.
• The primary endpoint of the trial is objective response rate (ORR), with secondary endpoints including progression-free survival (PFS), duration of response (DOR), and safety.
• The newly issued patent encompasses all mCRC patients, with RAS-mutated or RAS wild-type mCRC.
• Net cash used in operating activities for the first quarter of 2025 was approximately $12.8 million, an increase of approximately $5.1 million from $7.7 million for the same period in 2024.
• Total operating expenses were approximately $14.5 million for the three months ended March 31, 2025, an increase of $3.4 million from $11.1 million for the same period in 2024.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the completion of enrollment in the Phase 2 trial, the expansion of the intellectual property portfolio, and the sufficient cash runway. However, the increase in operating expenses and net cash used in operating activities temper the overall positive outlook.

Positives

• The completion of enrollment in the Phase 2 CRDF-004 trial is a significant milestone.
• The expansion of the intellectual property portfolio strengthens the company's position in the mCRC treatment landscape.
• The company has a strong cash position of $79.9 million, providing a runway into Q1 2027.
• Additional clinical data from the CRDF-004 trial is expected in the first half of 2025.

Negatives

• Net cash used in operating activities increased to $12.8 million in Q1 2025 from $7.7 million in Q1 2024.
• Total operating expenses increased to $14.5 million in Q1 2025 from $11.1 million in Q1 2024.

Risks

• Clinical trials involve a lengthy and expensive process with an uncertain outcome.
• Clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks.
• Results of preclinical studies or clinical trials for the product candidate could be unfavorable or delayed.
• The company may need additional financing.
• Business interruptions, including the outbreak of COVID-19 coronavirus and cyber-attacks, could harm the company's financial condition.
• There are uncertainties of government or third party payer reimbursement.
• The company is dependent on key personnel.
• There is substantial competition in the market.
• There are uncertainties of patent protection and litigation.
• The company is dependent upon third parties.
• There are risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations.

Future Outlook

The company believes its current cash resources are sufficient to fund its operations into Q1 2027 and expects additional clinical data from the ongoing CRDF-004 trial in mCRC in 1H 2025.

Management Comments

• Our lead program for onvansertib has remained on track in 2025 with the successful completion of enrollment in our trial in first-line RAS-mutated mCRC, underscoring our deep commitment to serving a patient population that has seen no therapeutic advancements in decades, said Mark Erlander, Chief Executive Officer of Cardiff Oncology.
• Furthermore, we expanded our intellectual property portfolio through the issuance of a second patent covering all mCRC, regardless of tumor mutational status, across all lines of therapy.
• As we continue to generate clinical data and move toward regulatory discussions with the FDA, we remain focused on our mission to deliver a transformative therapy that could redefine the standard of care for RAS-mutated mCRC and for other cancers.

Industry Context

Cardiff Oncology is focused on developing novel therapies for RAS-mutated mCRC, an area with limited therapeutic advancements, positioning them to potentially address a significant unmet medical need.

Comparison to Industry Standards

• It is difficult to compare Cardiff Oncology's results to industry standards without knowing the specific details of their clinical trial design and patient population.
• However, the completion of enrollment in a Phase 2 trial is a significant milestone for a clinical-stage biotechnology company.
• The expansion of their intellectual property portfolio also strengthens their competitive position.
• Other companies in the mCRC space include Amgen, Bayer, and Eli Lilly, but their approaches and specific targets may differ from Cardiff Oncology's PLK1 inhibition strategy.

Stakeholder Impact

• Shareholders may be positively impacted by the progress in clinical trials and the strong cash position.
• Patients with RAS-mutated mCRC may benefit from the development of new therapies.
• Employees are likely to be impacted by the company's growth and development.

Next Steps

• The company expects to release additional clinical data from the CRDF-004 trial in mCRC in the first half of 2025.
• The company will continue to generate clinical data and move toward regulatory discussions with the FDA.

Key Dates

Keywords

Cardiff Oncology, Onvansertib, mCRC, RAS-mutated, Clinical Trial, Phase 2, Patent, PLK1 Inhibition, Financial Results